查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017489

不可切除復發性大腸直腸癌：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Metastatic Colorectal Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 157 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計到 2025 年，mCRC 市場將達到 43 億美元，到 2035 年將達到 61 億美元，複合年成長率為 3.5-4%。
  • 推動市場成長的因素如下：符合藥物治療條件的患者人數增加（從 87,000 人增加到 91,000 人），標靶治療和生物製藥的應用範圍擴大，以及多線治療方案的改進。

不可切除復發性大腸直腸癌概述

不可切除的複發性結直腸癌（mCRC），也稱為IV期結直腸癌，是指起源於結腸或直腸的惡性細胞轉移到遠處器官（最常見的是肝臟和肺，較少見的是腹膜、腦和骨骼）。這種轉移的進展是大腸直腸癌患者死亡的主要原因。

儘管晚期疾病的根治性治療效果仍然有限，但治療方法的進步已顯著提高了患者的整體存活率和生活品質。治療方案高度個人化，取決於腫瘤的生物學特徵、分子譜和先前治療方案，並結合以下幾種治療方法：

  • 化療（FOLFOX、FOLFIRI方案）
  • 標靶治療（EGFR抑制劑、VEGF抑制劑、BRAF抑制劑）
  • 免疫療法（尤其適用於 MSI-H/dMMR 患者）

對於某些患者而言，轉移性切除術和肝臟標靶治療（消融、栓塞）在疾病控制和長期緩解的可能性中起著至關重要的作用。

主要亮點

  • mCRC 是一種醫療負擔沉重的癌症領域，因為相當一部分大腸直腸癌患者會發展為轉移性疾病。
  • 由於診斷率和存活率的提高，能夠接受藥物治療的患者人數仍然很多，而且還在增加。
  • 治療模式很大程度上依賴生物標記，根據以下標準對患者進行分類：腫瘤側別（左側與右側）和分子狀態（RAS/BRAF 突變、MSI 狀態）。
  • RAS 突變佔患者的 45-50%，而 BRAF 突變（8-10%）雖然不太常見，但卻構成了一個高風險亞群。
  • 治療方案包括多條線：
  • 第一線治療方案：化療+標靶治療（EGFR/VEGF）
  • 二線治療方案：根據抗藥性模式更換治療方法
  • 三線/四線治療：晚期分子標靶治療與補救性治療

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Mirati Therapeutics Inc.
  • Buzzard Pharmaceuticals
  • Parabilis Medicines, Inc.
  • Astellas Pharma Inc
  • Mirror Biologics, Inc.
  • Shanghai Kechow Pharma, Inc.
  • Suzhou Teligene Ltd.
  • AstraZeneca
  • Novartis Pharmaceuticals
  • Carina Biotech Limited
  • Treos Bio Limited
  • Cardiff Oncology
  • Alethia Biotherapeutics
  • Shanghai EpimAb Biotherapeutics Co., Ltd.
  • AbbVie
  • Hoffmann-La Roche
  • Menarini Group
  • Akeso
  • Riboscience, LLC.
  • Amgen
  • Qilu Pharmaceutical Co., Ltd.
  • Pfizer
  • BioNTech SE
  • Arcus Biosciences, Inc.
  • BeyondBio Inc.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Agenus Inc.
  • Bristol-Myers Squibb
  • Taizhou Mabtech Pharmaceutical Co.,Ltd
  • Incyte Biosciences International
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  • Hutchison Medipharma Limited
  • Hansoh BioMedical R&D;Company
  • Jiangsu Simcere Pharmaceutical Co., Ltd.
  • Luye Pharma Group Ltd.
  • Shanghai JMT-Bio Inc.
  • Summit Therapeutics
  • Erasca, Inc.
  • STCube, Inc.
  • CytoDyn, Inc.
  • Anbogen Therapeutics, Inc.
  • Isofol Medical AB
  • MedImmune LLC
  • Beijing Biotech
  • Vedanta Biosciences, Inc.
  • Pierre Fabre Medicament
  • Compass Therapeutics
  • Amal Therapeutics
  • MedPacto, Inc.
  • PureTech
  • IDEAYA Biosciences
  • Wugen, Inc.
  • Stingray Therapeutics
  • Evopoint Biosciences Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前療法
    • 重點
    • 診斷和治療過程/演算法
    • 主要治療方法概述及KOL洞察
  • 新興療法
    • 重點
    • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
    • 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興療法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Metastatic Colorectal Cancer Market Outlook

Thelansis's "Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Colorectal Cancer Overview

Metastatic colorectal cancer (mCRC), or Stage IV colorectal cancer, occurs when malignant cells originating in the colon or rectum spread to distant organs-most commonly the liver and lungs, and less frequently the peritoneum, brain, and bones. This metastatic progression is the primary driver of mortality in colorectal cancer.

While curative outcomes remain limited in advanced disease, therapeutic advancements have significantly improved overall survival and quality of life. Treatment is highly personalized and guided by tumor biology, molecular profile, and line of therapy, incorporating combinations of:

  • Chemotherapy (FOLFOX, FOLFIRI-based regimens)
  • Targeted therapies (EGFR inhibitors, VEGF inhibitors, BRAF inhibitors)
  • Immunotherapies (particularly in MSI-H/dMMR populations)

In select patients, metastasectomy and liver-directed therapies (ablation, embolization) play a critical role in disease control and potential long-term remission.

Key Highlights

  • mCRC represents a high-burden oncology segment, with a substantial proportion of colorectal cancer patients progressing to metastatic disease.
  • The drug-treatable patient population remains large and growing, supported by increasing diagnosis rates and improved survival outcomes.
  • Treatment paradigm is highly biomarker-driven, with segmentation based on: Tumor sidedness (left vs right) & Molecular status (RAS/BRAF mutations, MSI status)
  • RAS mutations account for 45-50% of patients, while BRAF mutations (8-10%) represent a smaller but high-risk subgroup.
  • Treatment is structured across multiple lines:
  • 1st line: chemo + targeted therapy (EGFR/VEGF)
  • 2nd line: therapy switch based on resistance patterns
  • 3rd/4th line: later-line targeted agents and salvage therapies

Market Overview

  • The mCRC market is valued at $4.3Bn in 2025, projected to reach $6.1Bn by 2035, reflecting a CAGR of 3.5-4%.
  • Market growth is driven by: Increasing drug-treatable population (87K to 91K patients), Expanded use of targeted therapies and biologics, Improved treatment sequencing across multiple lines

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • Mirati Therapeutics Inc.
  • Buzzard Pharmaceuticals
  • Parabilis Medicines, Inc.
  • Astellas Pharma Inc
  • Mirror Biologics, Inc.
  • Shanghai Kechow Pharma, Inc.
  • Suzhou Teligene Ltd.
  • AstraZeneca
  • Novartis Pharmaceuticals
  • Carina Biotech Limited
  • Treos Bio Limited
  • Cardiff Oncology
  • Alethia Biotherapeutics
  • Shanghai EpimAb Biotherapeutics Co., Ltd.
  • AbbVie
  • Hoffmann-La Roche
  • Menarini Group
  • Akeso
  • Riboscience, LLC.
  • Amgen
  • Qilu Pharmaceutical Co., Ltd.
  • Pfizer
  • BioNTech SE
  • Arcus Biosciences, Inc.
  • BeyondBio Inc.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Agenus Inc.
  • Bristol-Myers Squibb
  • Taizhou Mabtech Pharmaceutical Co.,Ltd
  • Incyte Biosciences International
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  • Hutchison Medipharma Limited
  • Hansoh BioMedical R&D Company
  • Jiangsu Simcere Pharmaceutical Co., Ltd.
  • Luye Pharma Group Ltd.
  • Shanghai JMT-Bio Inc.
  • Summit Therapeutics
  • Erasca, Inc.
  • STCube, Inc.
  • CytoDyn, Inc.
  • Anbogen Therapeutics, Inc.
  • Isofol Medical AB
  • MedImmune LLC
  • Beijing Biotech
  • Vedanta Biosciences, Inc.
  • Pierre Fabre Medicament
  • Compass Therapeutics
  • Amal Therapeutics
  • MedPacto, Inc.
  • PureTech
  • IDEAYA Biosciences
  • Wugen, Inc.
  • Stingray Therapeutics
  • Evopoint Biosciences Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)